---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-016620"
form_type: "8-K"
ticker: "ESPR"
cik: "0001434868"
company_name: "Esperion Therapeutics, Inc."
filed_at: "2023-05-09T23:59:59+00:00"
generated_at: "2026-06-15T08:45:22.283978+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Esperion Q1 net loss $61.7M; US product revenue +27% to $17M; Currax partnership

## Summary
- Total revenue $24.3M (+29% YoY); US net product revenue $17.0M (+27%); retail Rx equivalents +15% YoY.
- Net loss $61.7M vs $56.7M loss in Q1 2022; diluted EPS loss $0.79 vs $0.93.
- Pay-for-performance commercial partnership with Currax Pharmaceuticals to double promotional footprint.
- Regulatory filings for bempedoic acid label update expected in 1H 2023 in U.S. and Europe.
- Full-year 2023 operating expense guidance reaffirmed at $225-245M.

## SEC filing metadata
- accession: 0001628280-23-016620
- form_type: 8-K
- ticker: ESPR
- cik: 0001434868
- company_name: Esperion Therapeutics, Inc.
- filed_at: 2023-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434868/000162828023016620/0001628280-23-016620-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434868/000162828023016620/espr-20230509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-016620
- JSON: https://secwatch.observer/filing/0001628280-23-016620.json
- Plain text: https://secwatch.observer/filing/0001628280-23-016620.txt

## Key facts
- Earnings Releases
  Esperion Therapeutics, Inc. reported the first quarter ended March 31, 2023 results: revenue $24.3 million, net income $61.7 million, EPS $0.79. Guidance reaffirmed.
  - Period: the first quarter ended March 31, 2023
  - Revenue: $24.3 million
  - Net income: $61.7 million
  - EPS: $0.79
  - Guidance: reaffirmed
  - Result: reported results
  source text: the clinical trials comprising the CLEAR program, the Company’s pipeline, and information about cardiometabolic disease. First Quarter 2023 Financial Results Total revenue was $24.3 million, compared to $18.8 million for the comparable period in 2022, an increase of 29%. U.S. net product revenue was $17.0 million, compared to $13.4 million for the comparable period
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434868/000162828023016620/0001628280-23-016620-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.